Douglas M. Sproule is currently Vice President, Spinal Muscular Atrophy Therapeutic Area Head at AveXis, a role he has held since February 2016. Prior to this, he was Global Medical Affairs Director supporting the Pompe and Fabry disease franchises at Sanofi Genzyme. Before transitioning into industry, Douglas was an Assistant Professor in Neurology at Columbia University Medical Center, New York, where he completed fellowship training in pediatric neurology and neuromuscular neurology. He is board-certified in neurology with special qualification in child neurology and in neuromuscular medicine by the American Board of Psychiatry and Neurology. He has participated as principal investigator for numerous industry and government-sponsored clinical trials and has written or contributed to more than 30 publications in the area of neuromuscular disorders, including Spinal Muscular Atrophy and Duchenne Muscular Dystrophy